• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
June 24, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
June 22, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers BULL
News headline image
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
June 15, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
June 09, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 08, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness
June 04, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 01, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
May 27, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
May 20, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
May 19, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
May 14, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
May 08, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 07, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
April 16, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Provides Routine Update on Annual Filings
April 13, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
April 09, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
March 18, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Closing of its Rights Offering
March 06, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
March 04, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer
March 02, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering
February 27, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026
February 25, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
February 23, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering
February 12, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event
February 12, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Commencement of Rights Offering
February 11, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
February 06, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
February 05, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
News headline image
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering
January 27, 2026
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap